secwatch.observer — SEC 8-K summary
======================================

Issuer:     LUMOS PHARMA, INC. (—)
CIK:        0001126234
Form:       8-K
Filed at:   2024-05-15T23:59:59+00:00
Accession:  0001126234-24-000059
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lumos Pharma positive FDA End-of-Phase 2 meeting; Phase 3 trial plan with placebo control
--------------------------------------------------------------------------------

- FDA agreed placebo-controlled design for LUM-201 Phase 3 trial; 2:1 randomization, ~150 patients, 6-month placebo arm.
- Updated Phase 2 data show durable AHV: 12-month 8.2 cm/yr, 24-month 7.3 cm/yr (1.6 mg/kg) vs baseline 4.7 cm/yr.
- Cash $23.2M at March 31, 2024; expected to fund operations through Q3 2024; Q1 net loss $10.4M vs $7.3M year-ago.
- Full 12-month OraGrowtH212 data and additional analyses to be presented at ENDO in Q2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1126234/000112623424000059/0001126234-24-000059-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1126234/000112623424000059/lumo-20240515.htm
  HTML page:      https://secwatch.observer/filing/0001126234-24-000059

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer